Evidence map›Paper›PMID 21738816›Full record

ArticleInternational journal of clinical and experimental pathology2011

The proliferation markers Ki-67/MIB-1, phosphohistone H3, and survivin may contribute in the identification of aggressive ovarian carcinomas.

Guro Aune, Astrid K Stunes, Solveig Tingulstad, Oyvind Salvesen, Unni Syversen, Sverre H Torp

Open access · greenAbstract read
PubMed Full text at PMC
In one paragraph

Article in International journal of clinical and experimental pathology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed
8.9field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 64 citations in OpenAlex.

  1. Trial
  2. Article
  3. Cancer medicine · 2024
    Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Expression of CDK6 in Oral Squamous Cell CarcinomasAsian Pacific journal of cancer prevention : APJCP · 2018
    Article
  13. Detecting proliferation of adult hemocytes inWellcome open research · 2018
    Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. High phosphohistone H3 expression correlates with adverse clinical, biological, and pathological factors in neuroblastomas.The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society · 2015
    Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Guro AuneDepartment of Cancer Research and Molecular Medicine, Faculty of Medicine, Norwegian University of Science andTechnology (NTNU), Trondheim, Norway. guro.aune@ntnu.no
Astrid K Stunes
Solveig Tingulstad
Oyvind Salvesen
Unni Syversen
Sverre H Torp
Norwegian University of Science and Technology · NO

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The identification of new proliferation markers could have clinical implications in ovarian carcinoma by stratifying patients for treatment and follow-up. The aim of this study was to evaluate the diagnostic and prognostic value of the proliferation markers Ki-67/MIB-1, phosphorylated histone H3 (PHH3), and survivin in epithelial ovarian tumors. Ninety women with a pelvic mass who underwent surgery at the Department of Gynecological Oncology were included: 68 ovarian carcinomas, 11 borderline tumors, and 11 ovarian cystadenomas. We performed mitotic count and immunohistochemical analyses of Ki-67/MIB-1, PHH3, and survivin, related to clinicopathological parameters. Uni- and multivariate analyses of five-year overall survival were performed. We found statistically significant correlations between mitotic count, Ki-67/MIB-1, PHH3, and survivin. The expression of all proliferation markers was significantly higher in the carcinomas than in the borderline and benign tumors (p<0.05). There was, however an overlap of indices between the different malignancy groups. Women with advanced stage cancers (FIGO stage III and IV) had significantly higher tumor expression of all markers compared to patients with early stage cancers (FIGO stage I and II). Women with advanced disease and complete chemotherapy response had higher Ki67/MIB-1 expression than women without complete chemotherapy response. All markers had an impact on survival in the univariate analyses. In the multivariate analysis, however, only age and stage of disease reached statistical significance as prognostic factors. In conclusion, the proliferation markers Ki-67/MIB-1, PHH3, and survivin are positively correlated with each other and with tumor grade, and may contribute in the identification of aggressive ovarian carcinomas.

Indexed as

AdultAgedCarcinomaCell ProliferationCysteine Proteinase InhibitorsFemaleHistonesHumansImmunohistochemistryInhibitor of Apoptosis ProteinsKi-67 AntigenMiddle AgedMitotic IndexNeoplasm InvasivenessNeoplasm StagingOvarian NeoplasmsBIRC5 protein, humanCysteine Proteinase InhibitorsHistonesInhibitor of Apoptosis ProteinsKi-67 AntigenSurvivindiagnosisKi-67/MIB-1Ovarian carcinomaovaryPHH3proliferationsurvivalsurvivin

Identifiers

PMID21738816
PMCPMC3127066
OpenAlexW1898504109

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.